Fast Five Quiz: Herpes Zoster Risk Factors and Prevention

Ranjani Somayaji, MD


February 04, 2022

Vaccination is not required if a person has had primary varicella-zoster virus infection. In the pivotal phase 3 randomized controlled trial of the live-attenuated herpes zoster vaccine, administered as a single dose, the efficacy of the vaccine in persons older than 60 years was 51% for herpes zoster and 67% for preventing postherpetic neuralgia. The estimated duration of protection is 5 years.

The greatest risk for herpes zoster has been observed in patients with severely immunosuppressive conditions (eg, HIV, cancer); however, the live-attenuated vaccine is contraindicated in these individuals.

The live-attenuated herpes zoster vaccine is no longer available for use in the United States, but it is available in other countries, such as Canada and European Union countries.

Learn more about herpes zoster prevention.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.